Genentech recently won the patent for a psoriasis drug. Unfortunately, Roche’s Genentech unit prosecuted Eli Lilly for violation by claiming their psoriasis drugTalz, infringes on one of their patents.
This is the second partnership of the firm, the first outside oncology. It has a USD 790 million collaboration signed in 2016 with drugmaker Takeda of Japan. The deal with Zai Lab is the first for Crescendo to involve a specific pipeline asset. The deal with Takeda was more of a platform agreement giving it the required confidence to collaborate with other programs in oncology.
Forbion, one of the leading European life science venture capital firms, today announced that it led the $19 million Series B financing of Escalier Biosciences BV, a privately held biopharmaceutical company based in Nijmegen, The Netherlands. Escalier Biosciences is developing both oral and topical ROR?t drug candidates for psoriasis and other autoimmune diseases.
The National Institute for Health and Care Excellence has issued draft guidelines backing NHS use of Almirall’s Skilarence to treat moderate to severe plaque psoriasis.
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.